Shanghai Junshi Biosciences Co (SHSE:688180) Total Liabilities : ¥4,850 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shanghai Junshi Biosciences Co Total Liabilities?

Shanghai Junshi Biosciences Co's Total Liabilities for the quarter that ended in Dec. 2024 was ¥4,850 Mil.

Shanghai Junshi Biosciences Co's quarterly Total Liabilities increased from Jun. 2024 (¥4,384.46 Mil) to Sep. 2024 (¥4,577.67 Mil) and increased from Sep. 2024 (¥4,577.67 Mil) to Dec. 2024 (¥4,849.83 Mil).

Shanghai Junshi Biosciences Co's annual Total Liabilities increased from Dec. 2022 (¥2,782.04 Mil) to Dec. 2023 (¥4,022.26 Mil) and increased from Dec. 2023 (¥4,022.26 Mil) to Dec. 2024 (¥4,849.83 Mil).

Shanghai Junshi Biosciences Co Total Liabilities Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Total Liabilities Chart

Shanghai Junshi Biosciences Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

2,169.60

2,718.54

2,782.04

4,022.26

4,849.83

Shanghai Junshi Biosciences Co Quarterly Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															4,022.26	5,005.67	4,384.46	4,577.67	4,849.83

Shanghai Junshi Biosciences Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shanghai Junshi Biosciences Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2534.131	+	(2005.993	+	309.707
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	4,850

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	10800.088	-	5950.257
	=	4,850

Shanghai Junshi Biosciences Co's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2534.131	+	(2005.993	+	309.707
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	4,850

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	10800.088	-	5950.257
	=	4,850

Shanghai Junshi Biosciences Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (SHSE:688180) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

01877:Hong Kong 8SJ:Germany

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi Biosciences Co Ltd is a China-based biotechnology companyy with all-round capabilities in innovative drug discovery and development, clinical research on a global scale, large-scale production capacity to commercialization on the full industry chain. Aiming to develop first-in-class or bestin-class drugs by way of original innovation and co-development. Companies operations are located in the PRC and the USA.

Executives

	Directors, senior managers
Chen Ying Ge	senior management
Xiong Jun	Director
Yin Kan	senior management
Xie Wan	senior management

Shanghai Junshi Biosciences Co Headlines

No Headlines